WO2004105737A3 - Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents - Google Patents

Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents Download PDF

Info

Publication number
WO2004105737A3
WO2004105737A3 PCT/CA2004/000800 CA2004000800W WO2004105737A3 WO 2004105737 A3 WO2004105737 A3 WO 2004105737A3 CA 2004000800 W CA2004000800 W CA 2004000800W WO 2004105737 A3 WO2004105737 A3 WO 2004105737A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
various agents
methods relating
fibrous adhesions
inhibiting fibrous
Prior art date
Application number
PCT/CA2004/000800
Other languages
French (fr)
Other versions
WO2004105737A2 (en
Inventor
Johanne Cashman
Christopher Springate
Bruce Hay
Charles Winternitz
Original Assignee
Arc Pharmaceuticals Inc
Johanne Cashman
Christopher Springate
Bruce Hay
Charles Winternitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arc Pharmaceuticals Inc, Johanne Cashman, Christopher Springate, Bruce Hay, Charles Winternitz filed Critical Arc Pharmaceuticals Inc
Priority to JP2006529506A priority Critical patent/JP2007504273A/en
Priority to CA002527429A priority patent/CA2527429A1/en
Priority to BRPI0418384-3A priority patent/BRPI0418384A/en
Priority to EP04735180A priority patent/EP1631265A2/en
Priority to AU2004243513A priority patent/AU2004243513A1/en
Publication of WO2004105737A2 publication Critical patent/WO2004105737A2/en
Publication of WO2004105737A3 publication Critical patent/WO2004105737A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions.
PCT/CA2004/000800 2003-05-30 2004-05-28 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents WO2004105737A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006529506A JP2007504273A (en) 2003-05-30 2004-05-28 Pharmaceutical composition and method for inhibiting fibrous adhesion using various agents
CA002527429A CA2527429A1 (en) 2003-05-30 2004-05-28 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
BRPI0418384-3A BRPI0418384A (en) 2003-05-30 2004-05-28 pharmaceutical compositions and methods for inhibiting fibrous adhesions using various agents
EP04735180A EP1631265A2 (en) 2003-05-30 2004-05-28 Use of various agents for inhibiting fibrous adhesions
AU2004243513A AU2004243513A1 (en) 2003-05-30 2004-05-28 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US47490703P 2003-05-30 2003-05-30
US60/474,907 2003-05-30
US47765403P 2003-06-10 2003-06-10
US60/477,654 2003-06-10
US50525803P 2003-09-22 2003-09-22
US50525703P 2003-09-22 2003-09-22
US60/505,257 2003-09-22
US60/505,258 2003-09-22
US52080803P 2003-11-17 2003-11-17
US52057403P 2003-11-17 2003-11-17
US52080403P 2003-11-17 2003-11-17
US60/520,808 2003-11-17
US60/520,804 2003-11-17
US60/520,574 2003-11-17
US52913603P 2003-12-11 2003-12-11
US60/529,136 2003-12-11
US53366903P 2003-12-31 2003-12-31
US60/533,669 2003-12-31

Publications (2)

Publication Number Publication Date
WO2004105737A2 WO2004105737A2 (en) 2004-12-09
WO2004105737A3 true WO2004105737A3 (en) 2005-06-09

Family

ID=33494425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/000800 WO2004105737A2 (en) 2003-05-30 2004-05-28 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents

Country Status (8)

Country Link
EP (1) EP1631265A2 (en)
JP (1) JP2007504273A (en)
KR (1) KR20060034227A (en)
AU (1) AU2004243513A1 (en)
BR (1) BRPI0418384A (en)
CA (1) CA2527429A1 (en)
TW (1) TW200509949A (en)
WO (1) WO2004105737A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940786B2 (en) 2012-10-01 2015-01-27 Teikoku Pharma Usa, Inc. Non-aqueous taxane nanodispersion formulations and methods of using the same

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1809303T3 (en) * 2004-09-23 2019-06-11 Arc Medical Devices Inc PHARMACEUTICAL COMPOSITION AND METHODS IN RELATION TO FIBROSE ADHESION OR INFLAMMATORIC DISEASE USING LOW SULPHATE FUCAN
JP5129122B2 (en) 2005-04-26 2013-01-23 トリオン ファーマ ゲーエムベーハー Combination of antibodies and glucocorticoids for cancer treatment
US20060251702A1 (en) * 2005-05-05 2006-11-09 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
DE102005023170A1 (en) * 2005-05-19 2006-11-23 Curevac Gmbh Optimized formulation for mRNA
US8426381B2 (en) 2005-09-09 2013-04-23 Lucas Meyer Cosmetics Canada Inc. Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation
DE102008005172A1 (en) * 2008-01-19 2009-07-23 Mike Ehrlich Composition, useful for producing an agent for intraoperative application in abdominal cavity to prevent postoperative adhesion, comprises two components of polysaccharide, hyaluronic acid and/or phospholipid, and an antiinflammatory agent
US8865668B2 (en) 2008-02-20 2014-10-21 Devgen N.V. Methods and compositions for increasing RNA interference
US8440237B2 (en) 2009-04-27 2013-05-14 Mary Kay Inc. Botanical anti-acne formulations
JO3676B1 (en) 2009-07-27 2020-08-27 Arc Medical Devices Inc Pharmaceutical compositions comprising modified fucans and methods relating thereto
EP2566474B1 (en) 2010-05-03 2017-11-15 Teikoku Pharma USA, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
TWI382841B (en) 2010-10-29 2013-01-21 Univ China Medical Pharmaceutical composition for inhibiting inflammation
US8936635B2 (en) 2011-03-23 2015-01-20 Palmetto Pharmaceuticals Llc Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
US20130095160A1 (en) * 2011-09-12 2013-04-18 Gautam S. GHATNEKAR Resorbable polystatin biomaterials
US9138401B2 (en) 2011-12-19 2015-09-22 Mary Kay Inc. Combination of plant extracts to improve skin tone
US9421221B2 (en) 2012-11-12 2016-08-23 Warsaw Orthopedic, Inc. Compositions and methods for inhibiting adhesion formation
US9474767B2 (en) 2012-11-12 2016-10-25 Warsaw Orthopedic, Inc. Compositions and methods for inhibiting bone growth
US9707323B2 (en) 2012-11-12 2017-07-18 Warsaw Orthopedic, Inc. Devices and methods for inhibiting adhesion formation
ITTO20130317A1 (en) * 2013-04-19 2014-10-20 Idea Medical Devices S R L MEDICAL DEVICE INCLUDING A CHITOSAN-BASED SUPPORT STRUCTURE
CN103267842B (en) * 2013-05-15 2016-03-02 郭杰标 Detect the immune colloidal gold method of the illegal interpolation Diclofenac of Chinese patent drug
CA2913875A1 (en) 2013-05-29 2014-12-04 Otsuka Pharmaceutical Factory, Inc. Adhesion preventing material
US9566296B2 (en) 2013-11-08 2017-02-14 Warsaw Orthopedic, Inc. Multi-layered anti-adhesion device
EP3116469B1 (en) 2014-03-10 2018-10-03 Mary Kay, Inc. Skin lightening compositions
JP2021531392A (en) * 2018-07-27 2021-11-18 エーアールシー メディカル デバイス，インク． Highly purified fucan for the treatment of fibrotic adhesions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57167919A (en) * 1981-04-07 1982-10-16 Hirozo Ohira Preventing agent for intraperitoneal adhesion
WO1994000134A1 (en) * 1992-06-30 1994-01-06 Howmedica Inc. Preventing tissue adhesion using in situ modification of alginate
EP1027893A2 (en) * 1991-05-31 2000-08-16 Gliatech, Inc. Alginate containing medicament and implant for treating fibrosis
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
WO2001005370A1 (en) * 1999-07-16 2001-01-25 Samyang Corporation Antiadhesion barriers containing water-soluble alginate and carboxymethyl cellulose as major components and preparation method thereof
KR20010107067A (en) * 2000-05-25 2001-12-07 김정식 A conglutination inhibitor
WO2003018033A1 (en) * 2001-08-29 2003-03-06 The University Of British Columbia Use of fucans in the treatment of adhesions, arthritis and psoriasis
WO2004020473A1 (en) * 2002-08-27 2004-03-11 Lg Life Sciences Ltd. Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57167919A (en) * 1981-04-07 1982-10-16 Hirozo Ohira Preventing agent for intraperitoneal adhesion
EP1027893A2 (en) * 1991-05-31 2000-08-16 Gliatech, Inc. Alginate containing medicament and implant for treating fibrosis
WO1994000134A1 (en) * 1992-06-30 1994-01-06 Howmedica Inc. Preventing tissue adhesion using in situ modification of alginate
US6150581A (en) * 1995-06-07 2000-11-21 United States Surgical Corporation Chitosan/alginate anti-adhesion barrier
WO2001005370A1 (en) * 1999-07-16 2001-01-25 Samyang Corporation Antiadhesion barriers containing water-soluble alginate and carboxymethyl cellulose as major components and preparation method thereof
KR20010107067A (en) * 2000-05-25 2001-12-07 김정식 A conglutination inhibitor
WO2003018033A1 (en) * 2001-08-29 2003-03-06 The University Of British Columbia Use of fucans in the treatment of adhesions, arthritis and psoriasis
WO2004020473A1 (en) * 2002-08-27 2004-03-11 Lg Life Sciences Ltd. Microbeads of natural polysaccharide and hyaluronic acid and processes for preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198247, Derwent World Patents Index; Class A96, AN 1982-01099J, XP002303366 *
DATABASE WPI Section Ch Week 200256, Derwent World Patents Index; Class A97, AN 2002-525366, XP002303367 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940786B2 (en) 2012-10-01 2015-01-27 Teikoku Pharma Usa, Inc. Non-aqueous taxane nanodispersion formulations and methods of using the same
US9308195B2 (en) 2012-10-01 2016-04-12 Teikoku Pharma Usa, Inc. Non-aqueous taxane formulations and methods of using the same

Also Published As

Publication number Publication date
JP2007504273A (en) 2007-03-01
CA2527429A1 (en) 2004-12-09
KR20060034227A (en) 2006-04-21
WO2004105737A2 (en) 2004-12-09
TW200509949A (en) 2005-03-16
BRPI0418384A (en) 2007-06-26
EP1631265A2 (en) 2006-03-08
AU2004243513A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2004078712A3 (en) Isoquinoline derivatives and methods of use thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse
WO2007084424A3 (en) Treatment of substance abuse
WO2007087452A3 (en) Abuse resistant and extended release formulations and method of use thereof
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP2260835A3 (en) Composition for proteasome inhibition
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005032493A8 (en) Amide compounds as ion channel ligands and uses thereof
WO2005102392A3 (en) Combinations for treating hiv infection
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007112000A3 (en) Treatment of pain
WO2006034001A3 (en) Methods of treating hiv infection
EP1753777A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION USING TRIM5a
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
IL172773A (en) Formulations for the treatment of arthritis conditions
IL158181A0 (en) N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
WO2006093832A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480020645.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2527429

Country of ref document: CA

Ref document number: 2006529506

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: NL/a/2005/000091

Country of ref document: MX

Ref document number: 1020057022983

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 544431

Country of ref document: NZ

Ref document number: 2004243513

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004735180

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6173/DELNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004243513

Country of ref document: AU

Date of ref document: 20040528

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004243513

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004735180

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057022983

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0418384

Country of ref document: BR